Banting FG. Early work on insulin. Science. 1937;85:594–6.

Article  CAS  PubMed  Google Scholar 

Petersen J, Strømgaard K, Frølund B, Clemmensen C. Designing poly-agonists for treatment of metabolic diseases: challenges and opportunities. Drugs. 2019;79:1187–97.

Article  CAS  PubMed  Google Scholar 

Perreault L, Skyler JS, Rosenstock J. Novel therapies with precision mechanisms for type 2 diabetes mellitus. Nat Rev Endocrinol. 2021;17:364–77.

Article  CAS  PubMed  Google Scholar 

Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21:201–23.

Article  PubMed  Google Scholar 

Campbell JE, Müller TD, Finan B, DiMarchi RD, Tschöp MH, D’Alessio DA. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications. Cell Metab. 2023;35:1519–29.

Article  CAS  PubMed  Google Scholar 

Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol. 2023;19:201–16.

Article  CAS  PubMed  Google Scholar 

Tschöp M, Nogueiras R, Ahrén B. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia. 2023;66:1796–808.

Article  PubMed  PubMed Central  Google Scholar 

Nogueiras R, Nauck MA, Tschöp MH. Gut hormone co-agonists for the treatment of obesity: from bench to bedside. Nat Metab. 2023;5:933–44.

Article  CAS  PubMed  Google Scholar 

Maclean PS, Bergouignan A, Cornier M-A, Jackman MR. Biology’s response to dieting: the impetus for weight regain. Am J Physiol Regul Integr Comp Physiol. 2011;301:R581-600.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond). 2015;39:1188–96.

Article  CAS  PubMed  Google Scholar 

Sainsbury K, Evans EH, Pedersen S, Marques MM, Teixeira PJ, Lähteenmäki L, et al. Attribution of weight regain to emotional reasons amongst European adults with overweight and obesity who regained weight following a weight loss attempt. Eat Weight Disord. 2019;24:351–61.

Article  PubMed  Google Scholar 

Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.

Article  PubMed  Google Scholar 

Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753–61.

Article  CAS  PubMed  Google Scholar 

Arterburn DE, Olsen MK, Smith VA, Livingston EH, Van Scoyoc L, Yancy WS, et al. Association between bariatric surgery and long-term survival. JAMA. 2015;313:62–70.

Article  CAS  PubMed  Google Scholar 

Brissman M, Beamish AJ, Olbers T, Marcus C. Prevalence of insufficient weight loss 5 years after Roux-en-Y gastric bypass: metabolic consequences and prediction estimates: a prospective registry study. BMJ Open. 2021;11: e046407.

Article  PubMed  PubMed Central  Google Scholar 

Voorwinde V, Steenhuis IHM, Janssen IMC, Monpellier VM, van Stralen MM. Definitions of long-term weight regain and their associations with clinical outcomes. Obes Surg. 2020;30:527–36.

Article  PubMed  Google Scholar 

Noria SF, Shelby RD, Atkins KD, Nguyen NT, Gadde KM. Weight regain after bariatric surgery: scope of the problem, causes, prevention, and treatment. Curr Diab Rep. 2023;23:31–42.

Article  PubMed  PubMed Central  Google Scholar 

Debédat J, Sokolovska N, Coupaye M, Panunzi S, Chakaroun R, Genser L, et al. Long-term relapse of type 2 diabetes after Roux-en-Y gastric bypass: prediction and clinical relevance. Diabetes Care. 2018;41:2086–95.

Article  PubMed  Google Scholar 

Janssen P, Vanden Berghe P, Verschueren S, Lehmann A, Depoortere I, Tack J. Review article: the role of gastric motility in the control of food intake: review: regulation of food intake by gastric motility. Aliment Pharmacol Ther. 2011;33:880–94.

Article  CAS  PubMed  Google Scholar 

Juárez-Fernández M, Román-Sagüillo S, Porras D, García-Mediavilla MV, Linares P, Ballesteros-Pomar MD, et al. Long-term effects of bariatric surgery on gut microbiota composition and faecal metabolome related to obesity remission. Nutrients. 2021;13:2519.

Article  PubMed  PubMed Central  Google Scholar 

Guo Y, Huang Z-P, Liu C-Q, Qi L, Sheng Y, Zou D-J. Modulation of the gut microbiome: a systematic review of the effect of bariatric surgery. Eur J Endocrinol. 2018;178:43–56.

Article  CAS  PubMed  Google Scholar 

Ahmad NN, Pfalzer A, Kaplan LM. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes (Lond). 2013;37:1553–9.

Article  CAS  PubMed  Google Scholar 

Myronovych A, Kirby M, Ryan KK, Zhang W, Jha P, Setchell KD, et al. Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner. Obesity (Silver Spring). 2014;22:390–400.

Article  CAS  PubMed  Google Scholar 

Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Karns R, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509:183–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garibay D, McGavigan AK, Lee SA, Ficorilli JV, Cox AL, Michael MD, et al. β-cell glucagon-like peptide-1 receptor contributes to improved glucose tolerance after vertical sleeve gastrectomy. Endocrinology. 2016;157:3405–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Albaugh VL, He Y, Münzberg H, Morrison CD, Yu S, Berthoud H-R. Regulation of body weight: lessons learned from bariatric surgery. Mol Metab. 2023;68: 101517.

Article  CAS  PubMed  Google Scholar 

Sundbom M, Franzén S, Ottosson J, Svensson A-M. Superior socioeconomic status in patients with type 2 diabetes having gastric bypass surgery: a case-control analysis of 10 642 individuals. BMJ Open Diabetes Res Care. 2020;8: e000989.

Article  PubMed  PubMed Central  Google Scholar 

Alvarez R, Bonham AJ, Buda CM, Carlin AM, Ghaferi AA, Varban OA. Factors associated with long wait times for bariatric surgery. Ann Surg. 2019;270:1103–9.

Article  PubMed  Google Scholar 

Fulton S, Décarie-Spain L, Fioramonti X, Guiard B, Nakajima S. The menace of obesity to depression and anxiety prevalence. Trends Endocrinol Metab. 2022;33:18–35.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–32.

Article  CAS  PubMed  Google Scholar 

Müller TD, Clemmensen C, Finan B, DiMarchi RD, Tschöp MH. Anti-obesity therapy: from rainbow pills to polyagonists. Pharmacol Rev. 2018;70:712–46.

Article  PubMed  Google Scholar 

Williams DM, Nawaz A, Evans M. Drug therapy in obesity: a review of current and emerging treatments. Diabetes Ther. 2020;11:1199–216.

Article  PubMed  PubMed Central  Google Scholar 

Novikoff A, Müller TD. The molecular pharmacology of glucagon agonists in diabetes and obesity. Peptides. 2023;165: 171003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130.

Article  PubMed  PubMed Central  Google Scholar 

Brierley DI, Holt MK, Singh A, de Araujo A, McDougle M, Vergara M, et al. Central and peripheral GLP-1 systems independently suppress eating. Nat Metab. 2021;3:258–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith EP, An Z, Wagner C, Lewis AG, Cohen EB, Li B, et al. The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab. 2014;19:1050–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holter MM, Saikia M, Cummings BP. Alpha-cell paracrine signaling in the regulation of beta-cell insulin secretion. Front Endocrinol (Lausanne). 2022;13: 934775.